Insider trades
Open-market buys and sales that US company officers, directors and 10% owners file, newest filing first.
| Trade type | ||||||||
|---|---|---|---|---|---|---|---|---|
O'Neil Patrick R.EVP CLO & General Counsel | Ionis PharmaceuticalsIONS | Open-market sale10b5-1 plan | 06/26 | 06/30 | 3,069 sh | $80.00 | $245,520 | −4.8% |
Baroldi JosephEVP, Chief Business Officer | Ionis PharmaceuticalsIONS | Open-market sale10b5-1 plan | 06/26 | 06/30 | 5,635 sh | $80.16 | $451,701.6 | −54.7% |
Schneider EugeneEVP, Chf Clinical Develop Ofcr | Ionis PharmaceuticalsIONS | Open-market sale10b5-1 plan | 06/26 | 06/30 | 26,000 sh | $81.05 | $2,107,300 | −25.2% |
Ionis PharmaceuticalsIONS | Open-market sale10b5-1 plan | 06/24–06/26 | 06/26 | 85,637 sh3 trades | $79.70avg. | $6,825,482.93 | −25.9% | |
Swayze EricEVP Research | Ionis PharmaceuticalsIONS | Open-market sale10b5-1 plan | 06/25 | 06/26 | 10,602 sh | $79.18 | $839,466.36 | −32.8% |
Spencer R. BerthelsenDirector | Ionis PharmaceuticalsIONS | Open-market sale10b5-1 plan | 06/15 | 06/16 | 8,000 sh | $73.49 | $587,920 | −4.9% |
Ionis PharmaceuticalsIONS | Open-market sale10b5-1 plan | 06/12 | 06/16 | 60,846 sh2 trades | $73.40avg. | $4,466,282.46 | −73.0% | |
Spencer R. BerthelsenDirector | Ionis PharmaceuticalsIONS | Open-market sale10b5-1 plan | 06/01 | 06/03 | 8,000 sh | $75.67 | $605,360 | −4.9% |
Ionis PharmaceuticalsIONS | Open-market sale10b5-1 plan | 05/13–05/14 | 05/15 | 4,536 sh2 trades | $78.49avg. | $356,010.76 | −1.8% | |
Ionis PharmaceuticalsIONS | Open-market sale10b5-1 plan | 05/04 | 05/06 | 77,289 sh2 trades | $75.06avg. | $5,801,037.18 | −68.0% | |
Ionis PharmaceuticalsIONS | Open-market sale10b5-1 plan | 05/01 | 05/05 | 10,111 sh2 trades | $73.51avg. | $743,215.95 | −47.9% | |
Baroldi JosephEVP, Chief Business Officer | Ionis PharmaceuticalsIONS | Open-market sale10b5-1 plan | 04/28 | 04/30 | 1,626 sh | $71.79 | $116,730.54 | −3.5% |
Kyle JenneEVP, Chf GL Pdt Str Ofcr | Ionis PharmaceuticalsIONS | Open-market sale | 04/16 | 04/17 | 4,902 sh | $75.17 | $368,483.34 | −17.1% |
Baroldi JosephEVP, Chief Business Officer | Ionis PharmaceuticalsIONS | Open-market sale | 04/16 | 04/17 | 5,619 sh | $74.56 | $418,952.64 | −10.8% |
Birchler BrianEVP, Corp and Development Ops | Ionis PharmaceuticalsIONS | Open-market sale | 04/16 | 04/17 | 973 sh | $75.04 | $73,013.92 | −1.4% |
Ionis PharmaceuticalsIONS | Open-market sale10b5-1 plan | 04/15 | 04/17 | 5,000 sh2 trades | $76.27avg. | $381,366.52 | −8.9% | |
Devers Shannon L.EVP, Chief Human Resources Ofc | Ionis PharmaceuticalsIONS | Open-market sale10b5-1 plan | 04/02 | 04/02 | 6,193 sh | $74.05 | $458,591.65 | −27.5% |
Ionis PharmaceuticalsIONS | Open-market sale10b5-1 plan | 04/01 | 04/02 | 22,321 sh2 trades | $75.54avg. | $1,686,232.7 | −67.0% | |
Schneider EugeneEVP, Chf Clinical Develop Ofcr | Ionis PharmaceuticalsIONS | Open-market sale10b5-1 plan | 03/19 | 03/23 | 5,812 sh | $70.97 | $412,477.64 | −8.3% |
Ionis PharmaceuticalsIONS | Open-market sale10b5-1 plan | 03/16–03/17 | 03/18 | 225,220 sh3 trades | $72.43avg. | $16,313,547.96 | −73.2% |